User:Melvin Chang/sandbox

Dostarlimab is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor to block its activity with PD-L1 and PD-L2, which allows for the anti-tumor response that was previously inhibited by PD-1.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Dostarlimab. [Updated 2022 Jun 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581977/